Butyrate suppresses mucosal inflammation in inflammatory bowel disease primarily through HDAC3 inhibition in monocytes and macrophages
The FEBS Journal · 2025-11 · 292 (22) · 6134-6157
DOI: 10.1111/febs.70289 ↗Kurz gefasst
Fachartikel in der Zeitschrift The FEBS Journal, online erschienen am 19.10.2025. Verfasst von Daniela Parada-Venegas und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, The Netherlands. Hauptthemen laut MEDLINE: Histone Deacetylases, Inflammatory Bowel Diseases, Macrophages, Butyrates. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Universidad de Chile, Agencia Nacional de Investigación y Desarrollo, Stichting De Cock-Hadders.
Abstract (Originalsprache)
Butyrate‐producing gut bacteria and luminal butyrate levels are reduced in Inflammatory Bowel Diseases (IBDs). Butyrate has anti‐inflammatory properties through mechanisms not well‐characterized in IBDs. Here, we determined the butyrate anti‐inflammatory effect on primary IBD tissues and intestinal cell models to identify key target cells and pathway(s) involved. Cytokines, monocarboxylate transporter‐1 (MCT1), G‐protein‐coupled receptor‐109A (GPR109A), and histone deacetylase‐3 (HDAC3) levels were analyzed in IBD and healthy tissues using cytometric bead arrays, RNA‐seq analysis and immunofluorescence. Inflammatory markers and phagocytosis in butyrate‐treated colonic organoids, primary monocytes or THP‐1 macrophages, were assessed by qPCR, flow cytometry and amikacin protection assays, when relevant combined with GPR109A or HDAC3 antagonists. Butyrate suppressed TNF and IL‐6 secretion by > 50% in ex vivo ‐cultured inflamed IBD biopsies. MCT1 expression was reduced in inflamed epithelium and cytokine‐exposed organoids, while IL‐18 was reduced 0.5‐fold in organoids, and both were restored by butyrate, without suppressing pro‐inflammatory gene expression. GPR109A and HDAC3 were elevated in IBD tissues and upregulated by butyrate in cultured mucosa. Butyrate also suppressed IL‐6, TNF‐α, CD40, and CD80 by > 50% and enhanced adherent‐invasive Escherichia coli (AIEC) phagocytosis by 62% in monocytes/macrophages. Histone acetylation (H3K9ac) increased > 5‐fold, mimicking the HDAC inhibitor SAHA. Contrary, specific GPR109A inhibition and gene G‐protein‐coupled receptor inhibition did not alter butyrate's effects. Butyrate restores MCT1 and IL‐18 gene expression in inflamed epithelial cells, showing limited anti‐inflammatory effects. Instead, butyrate targets HDAC3 in mononuclear cells, suppressing inflammation in IBD gut mucosa. The cell‐type‐specific effects of butyrate offer mechanistic insights that support its therapeutic relevance in IBDs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, The Netherlands.
- Innate Immunity Laboratory, Immunology Program, Biomedical Sciences Institute, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
- Center of Biomedical Research (CIBMED), School of Medicine UFT-CLC, Universidad Finis Terrae, Santiago, Chile.
- Intestinal Immune Regulation (I2R) Lab, Department of Medical Technology, Faculty of Medicine, Universidad de Chile, Santiago, Chile.
- Gastroenterology Section, Department of Internal Medicine, Hospital Clínico Universidad de Chile José Joaquín Aguirre, Santiago, Chile.
- Academic Research Unit, Clínica Las Condes, Santiago, Chile.
ORCID-Profile: Daniela Parada-Venegas, Klaas Nico Faber, Marcela A Hermoso
Förderung
- Universidad de Chile
- Agencia Nacional de Investigación y Desarrollo
- Stichting De Cock-Hadders
- University Medical Center Groningen/University of Groningen PhD scholarship
- Fondo Nacional de Desarrollo Científico y Tecnológico
Zitieren
APA
Parada-Venegas, D., De la Fuente López, M., Dubois-Camacho, K., Landskron, G., Blokzijl, T., Molina, H., Casanova, M. C., Cui, Y., Liu, M., Da Costa De Pina, A. M., Simian, D., González, M. J., Weersma, R. K., Quera, R., Dijkstra, G., Faber, K. N., & Hermoso, M. A. (2025). Butyrate suppresses mucosal inflammation in inflammatory bowel disease primarily through HDAC3 inhibition in monocytes and macrophages. The FEBS Journal, 292(22), 6134-6157. https://doi.org/10.1111/febs.70289
Vancouver
Parada-Venegas D, De la Fuente López M, Dubois-Camacho K, Landskron G, Blokzijl T, Molina H, et al. Butyrate suppresses mucosal inflammation in inflammatory bowel disease primarily through HDAC3 inhibition in monocytes and macrophages. The FEBS Journal. 2025;292(22):6134-6157. doi:10.1111/febs.70289
BibTeX
@article{ParadaVenegas2025,
author = {Parada-Venegas, Daniela and De la Fuente López, Marjorie and Dubois-Camacho, Karen and Landskron, Glauben and Blokzijl, Tjasso and Molina, Héctor and Casanova, María-Celeste and Cui, Yingying and Liu, Moting and Da Costa De Pina, Antonio M and Simian, Daniela and González, María-Julieta and Weersma, Rinse K and Quera, Rodrigo and Dijkstra, Gerard and Faber, Klaas Nico and Hermoso, Marcela A},
title = {Butyrate suppresses mucosal inflammation in inflammatory bowel disease primarily through HDAC3 inhibition in monocytes and macrophages},
journal = {The FEBS Journal},
year = {2025},
volume = {292},
number = {22},
pages = {6134--6157},
doi = {10.1111/febs.70289}
}
EUVIMED